Alder raises $38 million in Series D round to advance cancer, migraine and other programs
This article was originally published in Scrip
Executive Summary
Alder Biopharmaceuticals is in the enviable position of having raised $38 million in a Series D round led by new investor Novo Ventures at a time when the company didn't necessarily need the money.